liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease
Univ Helsinki, Finland; Helsinki Univ Hosp, Finland; Minerva Fdn, Finland.
Univ Helsinki, Finland; Helsinki Univ Hosp, Finland; Minerva Fdn, Finland.
Nordic Biosci Biomarkers & Res, Denmark.
VLVbio AB, Sweden.
Show others and affiliations
2022 (English)In: Journal of Clinical Endocrinology and Metabolism, ISSN 0021-972X, E-ISSN 1945-7197, Vol. 107, no 5, p. e2008-e2020Article in journal (Refereed) Published
Abstract [en]

Context: Guidelines recommend blood-based fibrosis biomarkers to identify advanced nonalcoholic fatty liver disease (NAFLD), which is particularly prevalent in patients with obesity. Objective: To study whether the degree of obesity affects the performance of liver fibrosis biomarkers in NAFLD. Design: Cross-sectional cohort study comparing simple fibrosis scores [Fibrosis-4 Index (FIB-4); NAFLD Fibrosis Score (NFS); aspartate aminotransferase to platelet ratio index; BARD (body mass index, aspartate-to-alanine aminotransferase ratio, diabetes); Hepamet Fibrosis Score (HFS)] and newer scores incorporating neo-epitope biomarkers PRO-C3 (ADAPT, FIBC3) or cytokeratin 18 (MACK-3). Setting: Tertiary referral center. Patients: We recruited overweight/obese patients from endocrinology (n = 307) and hepatology (n = 71) clinics undergoing a liver biopsy [median body mass index (BMI) 40.3 (interquartile range 36.0-44.7) kg/m(2)]. Additionally, we studied 859 less obese patients with biopsy-proven NAFLD to derive BMI-adjusted cutoffs for NFS. Main Outcome Measures: Biomarker area under the receiver operating characteristic (AUROC), sensitivity, specificity, and predictive values to identify histological stage >= F3 fibrosis or nonalcoholic steatohepatitis with >= F2 fibrosis [fibrotic nonalcoholic steatohepatitis (NASH)]. Results: The scores with an AUROC >= 0.85 to identify >= F3 fibrosis were ADAPT, FIB-4, FIBC3, and HFS. For fibrotic NASH, the best predictors were MACK-3 and ADAPT. The specificities of NFS, BARD, and FIBC3 deteriorated as a function of BMI. We derived and validated new cutoffs for NFS to rule in/out >= F3 fibrosis in groups with BM Is <30.0, 30.0 to 39.9, and >= 40.0 kg/m(2). This optimized its performance at all levels of BMI. Sequentially combining FIB-4 with ADAPT or FIBC3 increased specificity to diagnose >= F3 fibrosis. Conclusions: In obese patients, the best-performing fibrosis biomarkers are ADAPT and the inexpensive FIB-4, which are unaffected by BMI. The widely used NFS loses specificity in obese individuals, which may be corrected with BMI-adjusted cutoffs.

Place, publisher, year, edition, pages
Oxford University Press, 2022. Vol. 107, no 5, p. e2008-e2020
Keywords [en]
nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; fibrosis; cirrhosis; biomarkers; obesity
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:liu:diva-183250DOI: 10.1210/clinem/dgab933ISI: 000756736100001PubMedID: 34971370OAI: oai:DiVA.org:liu-183250DiVA, id: diva2:1642182
Note

Funding Agencies|Academy of FinlandAcademy of Finland [309263]; Novo Nordisk FoundationNovo Nordisk FoundationNovocure Limited; Sigrid Juselius FoundationSigrid Juselius Foundation; Orion Research Foundation sr; Yrjo Jahnsson Foundation sr; Maud Kuistila Memorial Foundation sr; Emil Aaltonen Foundation sr; Italian Ministry of Health (Ministero della Salute, Ricerca Finalizzata) [RF-2016-02364358]; Ricerca Corrente Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico; Fondazione IRCCS Ca Granda core COVID-19 Biobank [RC100017A]; Fondazione IRCCS Ca Granda "Liver BIBLE" [PR-0391]

Available from: 2022-03-04 Created: 2022-03-04 Last updated: 2025-02-11

Open Access in DiVA

fulltext(1335 kB)356 downloads
File information
File name FULLTEXT01.pdfFile size 1335 kBChecksum SHA-512
95593becbf704e123e4b96e4c2e54992cff996e3198b533e8cf0eb7edfd341a0182c184bdb9799610ed65364acb1670fb1814f7dd150b047647394744848e556
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records

Kechagias, StergiosEkstedt, Mattias

Search in DiVA

By author/editor
Kechagias, StergiosEkstedt, Mattias
By organisation
Division of Diagnostics and Specialist MedicineFaculty of Medicine and Health SciencesMag- tarmmedicinska kliniken
In the same journal
Journal of Clinical Endocrinology and Metabolism
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar
Total: 357 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 324 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf